Search

Displaying results 9631 - 9640 of 9726 in total
  1. Drug

    Bisoctrizole

    go.drugbank.com/drugs/DB11262
    Approved

    It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B rays. … Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of

  2. Drug

    Dihydro-alpha-ergocryptine

    go.drugbank.com/drugs/DB11274
    Approved

    These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. … Alpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049]

  3. Drug

    Zolazepam

    go.drugbank.com/drugs/DB11555
    ExperimentalVet approved

    Zolazepam is a pyrazolodiazepinone derivative used as an anaesthetic in veterinary medicine.

  4. Drug

    Asunaprevir

    go.drugbank.com/drugs/DB11586
    ApprovedWithdrawn

    Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. … It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.

  5. Drug

    Domiphen

    go.drugbank.com/drugs/DB11594
    Approved

    Domiphen bromide is a quaternary ammonium compound that is predominantly employed as a topically administered antiseptic agent.

  6. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...

  7. Drug

    Vinflunine

    go.drugbank.com/drugs/DB11641
    ApprovedInvestigational

    While these patients have a median survival of approximately 4 months and a poor prognosis [L1396], there is currently no standard therapy in patients with advanced urothelial carcinoma [A32626]. … Some patients with advanced urothelial carcinoma experience inadequate therapeutic response from a prior platinum-containing regimen.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  8. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. … Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy.

  9. Drug

    Curcumin

    go.drugbank.com/drugs/DB11672
    ApprovedInvestigational

    It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities [A33166].

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. … Therefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity, demonstrated the feasibility of the small-molecule inhibitor approach.